-
Ifinatamab Deruxtecan Elicits Responses in Previously Treated Extensive-Stage Small Cell Lung Cancer
08 Sep 2025 00:53 GMT
… of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.1 … (Zepzelca; 21.2%), amrubicin (8.8%), DLL3-targeting … of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September … with relapsed small cell lung cancer (IDeate-Lung02). Clinical …
-
Greek Researchers Lead Breakthrough Lung Cancer Study
02 Aug 2025 00:20 GMT
… drugs, including topotecan, lurbinectedin, or amrubicin. Results from the interim analysis … planned for World Lung Cancer Day
Coinciding with World Lung Cancer Day on Aug … of immunotherapy in small-cell lung cancer healthcare.
Greek contribution draws …
-
OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025
21 Jun 2025 02:01 GMT
… transforming the treatment landscape for lung cancer, offering new hope for patients … with both small cell lung cancer (SCLC) and non-SCLC (NSCLC … ; Jazz), topotecan (Hycamtin; Sandoz), and amrubicin (Calsed; Nippon Kayaku). The results …
-
Phase III DeLLphi-304 Trial Finds Imdelltra Significantly Extends Survival in Relapsed Small-Cell Lung Cancer
10 Jun 2025 16:07 GMT
… with relapsed small-cell lung cancer (SCLC) compared to … patients with small-cell lung cancer (SCLC) whose disease … topotecan, lurbinectedin, or amrubicin, while producing improvements in … in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …
-
Tarlatamab Significantly Improves Survival in Patients With Small Cell Lung Cancer Post-Progression
06 Jun 2025 15:31 GMT
… topotecan, lurbinectedin, or amrubicin. They were further stratified … in Relapsed Small Cell Lung Cancer (DeLLphi-304). National … in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301 … DLL3 in small cell lung cancer and other neuroendocrine carcinomas. …
-
Imdelltra Shows Survival Benefit in Small Cell Lung Cancer
04 Jun 2025 03:06 GMT
… cytologically confirmed small cell lung cancer who experienced disease progression … topotecan (185 patients), or amrubicin (23 patients). Stratification factors … intended chemotherapy (topotecan/amrubicin versus lurbinectedin).
Overall survival served …
-
Dellphi-304 Data Reinforce Role of Tarlatamab as Second-Line SOC in Small Cell Lung Cancer
03 Jun 2025 05:19 GMT
… immunotherapies for our patients with lung cancer.”
Rudin is deputy director of … = 47), topotecan (n = 185), or amrubicin (n = 23). Stratification factors included … ), and intended chemotherapy (topotecan/amrubicin vs lurbinectedin).
OS served as …
-
Results from IDeate─Lung01 phase 2 trial shows ifinatamab deruxtecan demonstrated clinically meaningful response rates in patients with extensive─stage SCLC
09 Sep 2025 05:30 GMT
… 2025 World Conference on Lung Cancer hosted by the International … extensive-stage small cell lung cancer,” said Ken Takeshita, MD … regulatory authorities.”
“Small cell lung cancer is the second most … 1%), lurbinectedin (21.2%), amrubicin (8.8%) and DLL3- …
-
Evolving Options for SCLC Management Drive the Need for Increasingly Personalized Approaches
08 Sep 2025 13:43 GMT
… set the small cell lung cancer (SCLC) treatment paradigm on … tarlatamab over topotecan and amrubicin. The data may still … ) treatment for small cell lung cancer (SCLC): primary analysis of … with extensive-stage small cell lung cancer (ES-SCLC): primary results …
-
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
08 Jan 2025 13:10 GMT
… extensive-stage small cell lung cancer (ES-SCLC).
“This … Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin … phase III trial of amrubicin versus topotecan as second … cell lung cancer progression after 2 lines of therapy. Lung Cancer. …
About
© 1995-2025